Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-24-134598
Filing Date
2024-12-09
Accepted
2024-12-09 16:37:35
Documents
2
Period of Report
2024-12-05

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 2162
2 EX-24.POA achv-ex24_poa.htm EX-24.POA 13682
  Complete submission text file 0000950170-24-134598.txt   17527
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Issuer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address C/O ALEXZA PHARMACEUTICALS INC 2091 STIERLIN COURT MOUNTAIN VIEW CA 94043
Business Address
Oki Mark K (Reporting) CIK: 0001491847 (see all company filings)

Type: 3 | Act: 34 | File No.: 033-80623 | Film No.: 241535569